Study of anticancer effects of the combination of cisplatin and topotecan on endometrial cancer in nude mice

付莉,朱丹,赵怡璇,李守柔
DOI: https://doi.org/10.3969/j.issn.1001-4411.2007.16.046
2007-01-01
Abstract:Objective:To evaluate the anticancer effects of topotecan,cisplatin,the combination of topotecan and cisplatin on human endometrial cancer in nude mice.Methods:The human endometrial cancer cell line of AN3CN were subcutaneously implanted on the back of nude mice.When the tumor had developed,the forty nude mice were divided into 4 groups randomly including topotecan group,cisplatin group,combination group and control group.Different chemical therapy was served through intraperitoneal injection,and all mice were sacrificed after 36 days.The measurement of tumor volumes,growth curve of tumor and the inhibiting rates of tumor growth were performed in each group.And the growth cycle of tumor cell was detected by flow cytometry.Results:Significant differences in tumor growth inhibiting rates were found between the treatment groups and the control group(P<0.05).The tumor growth inhibiting rates of the combination group were significantly superior to that of opotecan group or cisplatin group(P<0.05).The cell amount of G0/G1 stage in combination group was significant increased than that in topotecan group or control group(P<0.05).Conclusion:Due to the synergic anticancer effect,the effect of the combination of topotecan and cisplatin has stronger inhibition on endometrial cancer than that of the single use topotecan or cisplatin.
What problem does this paper attempt to address?